Welcome to our dedicated page for Quantum-Si Incorporated news (Ticker: QSI), a resource for investors and traders seeking the latest updates and insights on Quantum-Si Incorporated stock.
Quantum-Si Incorporated (symbol: QSI) is revolutionizing the field of proteomics with cutting-edge technologies. The company has developed a unique semiconductor chip that enables single-molecule, next-generation protein sequencing and genomics, going beyond traditional DNA sequencing. This innovation is set to digitize proteomic research, significantly advancing drug discovery and diagnostics.
Founded by successful entrepreneurs and fully funded to focus on groundbreaking science, Quantum-Si fosters an environment where highly committed individuals are encouraged to solve tough problems and create impactful technologies. The company is headquartered in Guilford, Connecticut, and continues to attract bright minds dedicated to transforming healthcare.
Quantum-Si's core products include a suite of technologies that leverage their proprietary semiconductor chip for high-precision protein analysis. These products are designed to provide deeper insights into the proteome, which is essential for understanding diseases, developing new therapies, and personalizing medicine.
Recent achievements highlight Quantum-Si's commitment to innovation and excellence. The company has formed strategic partnerships with leading research institutions and pharmaceutical companies to accelerate the adoption of its technologies. Additionally, Quantum-Si continues to invest in research and development to enhance its product offerings and expand its market reach.
Financially, Quantum-Si is backed by substantial funding from its founders, allowing the company to prioritize innovation and market entry without the immediate pressures of profitability. This financial stability ensures that the company can focus on long-term goals and sustainable growth.
For those interested in joining a dynamic and innovative team, Quantum-Si offers a range of career opportunities. Visit their job postings at 4Catalyzer to learn more about current openings.
Empower discovery. Empower health. Empower you.
Quantum-Si Incorporated (NASDAQ: QSI) announced a partnership with Biovista to enhance drug discovery through advanced protein sequencing and AI visualization technology. This collaboration aims to speed up protein drug target discovery by allowing researchers to analyze connections between proteins, diseases, and drug mechanisms. The integration of Biovista's VIZIT™ tool into Quantum-Si's cloud-based suite enhances proteomic workflows, facilitating the discovery of new therapeutic targets and biomarkers.
Quantum-Si Incorporated (NASDAQ: QSI), known as The Protein Sequencing Company™, will participate in the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA, from January 9-12, 2023. The company's management is set to present on January 12 at 10:30 am PST, discussing recent advancements including the launch of their innovative Platinum™ instrument, which enables next-generation single-molecule protein sequencing. A live and archived webcast will be available on the Quantum-Si website for those unable to attend.
Quantum-Si (NASDAQ: QSI) announced the launch of Platinum™, the first next-generation single-molecule protein sequencing platform, now available for $70,000. This innovative technology is expected to revolutionize the field of proteomics by providing broad access to high-resolution protein sequencing data, facilitating advancements in drug discovery and diagnostics. The company also appointed Grace Johnston, PhD, as Chief Commercial Officer to lead global sales and commercial activities. Shipments for the new platform are set to begin in Q1 2023.
Quantum-Si, known as The Protein Sequencing Company™, has joined the Human Proteome Organization (HUPO) Industrial Advisory Board. This collaboration aims to advance proteomics technologies and enhance understanding of human diseases. Dan Hanson and Dr. Brian Reed will represent Quantum-Si, which is actively participating in HUPO's 21st World Congress in Cancun and the upcoming US HUPO Conference in Chicago. CEO Jeff Hawkins emphasized the importance of protein sequencing in revolutionizing life science research and drug discovery.
Quantum-Si (Nasdaq: QSI) reported its third-quarter 2022 financial results, showing a net loss of $31.7 million, up from $18.1 million in Q3 2021. Operating expenses rose to $27.7 million, a 9.9% increase year-over-year, mainly driven by R&D costs reaching $16.7 million, compared to $11.1 million in the prior year. However, the company is lowering its operating expense growth guidance to 25-30% for 2022, down from 40-50%. Quantum-Si aims to launch its Platinum protein sequencing instrument by year-end 2022 and is managing costs effectively as it prepares for commercialization.
Quantum-Si (NASDAQ: QSI) announced its participation in the 16th Annual Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 17, 2022, in New York. CEO Jeff Hawkins and COO Patrick Schneider will engage in a fireside chat at 3:30 pm ET, discussing advancements in the commercialization of their innovative Platinum™ protein sequencing instrument, aimed at revolutionizing proteomics. A live and archived webcast will be available in the Investors section of the Quantum-Si website.
Quantum-Si Incorporated (NASDAQ: QSI) will announce its third-quarter 2022 financial results on November 7, 2022, after market close. Management will host a conference call at 4:30 p.m. ET on the same day to discuss these results and provide a business update. Quantum-Si focuses on advancing proteomics through its innovative semiconductor chip designed for single-molecule protein sequencing, enhancing drug discovery and diagnostics beyond traditional DNA sequencing methods.
Quantum-Si, a life sciences company (NASDAQ: QSI), announced a groundbreaking development in protein sequencing technology. Published in Science, their research presents a next-generation single-molecule protein sequencing platform utilizing semiconductor chips and Time Domain Sequencing™, offering real-time amino acid insights. This innovation promises to enhance drug discovery and diagnostics, significantly impacting biomedical research. Founded by Dr. Jonathan Rothberg, Quantum-Si aims to redefine proteomics, facilitating greater understanding of proteins and their roles in health and disease.
Quantum-Si Incorporated (NASDAQ: QSI) has appointed Jeff Hawkins as its new Chief Executive Officer, effective October 10, 2022. Hawkins succeeds Dr. Jonathan Rothberg, who has been Interim CEO since the company's founding. With over 20 years in life sciences, Hawkins previously led significant growth at Illumina and Truvian Sciences. He will oversee the launch of Quantum-Si's Platinum™ instrument, the first next-generation single-molecule protein sequencing platform. This transition aims to propel the company into a new growth phase.
Quantum-Si Incorporated (Nasdaq: QSI) announced participation in the Morgan Stanley 20th Annual Global Healthcare Conference from September 12-14, 2022, in New York, NY. Patrick Schneider, President and COO, will engage in a fireside chat on September 14, 2022, at 10:35 am ET. The discussion will focus on the company's advancements toward commercialization of the Platinum™ instrument, a pioneering platform for single-molecule protein sequencing. A live and archived webcast will be available in the Investors section of Quantum-Si's website.
FAQ
What is the current stock price of Quantum-Si Incorporated (QSI)?
What is the market cap of Quantum-Si Incorporated (QSI)?
What does Quantum-Si Incorporated do?
What is the significance of Quantum-Si's semiconductor chip?
Where is Quantum-Si headquartered?
Who funds Quantum-Si?
What are Quantum-Si's core products?
What recent achievements has Quantum-Si made?
What opportunities are available at Quantum-Si?
How does Quantum-Si contribute to healthcare?
What is the financial condition of Quantum-Si?
How can I stay updated with the latest news about Quantum-Si?
